Children's Viewing Behavior

NCT07229365 | Recruiting FDA Device

• 1 other identifier: CPRO-2507-002
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to investigate the area of the spectacle lens in which a subject is viewing through regardless of task being performed.

Conditions

Myopia; Myopia Progression; Juvenile Myopia

Outcome Measures

Primary Outcomes (3)

• Activity dependent, gaze location in myopia control spectacles

  2 months

• Subjective/objective quantification of activity via survey or observation

  2 months

• Pupil size

  2 months

Study Arms (2)

SightGlass Vision Test Arm 1

EXPERIMENTAL

Single vision, impact-resistant spectacle lenses

Device: Novel spectacle lens design

SightGlass Vision Test Arm 2

EXPERIMENTAL

Single vision, impact-resistant spectacle lenses

Device: Spectacle lenses

Interventions

Novel spectacle lens design DEVICE

Use of lenses may reduce the rate of progression of juvenile myopia

SightGlass Vision Test Arm 1

Spectacle lenses DEVICE

Use of lenses may reduce the rate of progression of juvenile myopia

SightGlass Vision Test Arm 2

Eligibility Criteria

• Age: 7 Years - 14 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)

You may qualify if:

• Is 7-14 years of age, inclusive
• Requires spherical spectacle lenses within the power range available for the study lenses
• Parent/guardian has read and understood the informed consent form, and the child has provided age-appropriate assent
• Is willing and able to follow instructions and maintain the appointment schedule
• Is correctable to a visual acuity of 20/40 or better (in each eye) with their habitual vision correction or 20/20 best corrected
• Has had a self-reported oculo-visual examination in the last two years
• Spectacle cylinder of ≤ -0.75DC in both eyes

You may not qualify if:

• A person will be excluded from the study if he/she:
• Is unable to complete the necessary study activities
• Has any systemic disease affecting ocular health
• Is using any systemic or topical medications (including pharmaceutical myopia control therapy) that will affect ocular health
• Is aphakic

Sponsors & Collaborators

• SightGlass Vision, Inc.: lead

Study Sites (1)

Indiana University

Bloomington, Indiana, 47405, United States

RECRUITING

MeSH Terms

Conditions

Myopia

Condition Hierarchy (Ancestors)

Refractive Errors; Eye Diseases

Central Study Contacts

Jennifer Hill

CONTACT

6783614877; jhill@sightglassvision.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 12, 2025
• First Posted: November 17, 2025
• Study Start: December 22, 2025
• Primary Completion (Estimated): December 30, 2026
• Study Completion (Estimated): July 1, 2027
• Last Updated: April 30, 2026

Record last verified: 2026-04

Locations

US (1)